iRadimed (IRMD) Competitors $71.23 -0.40 (-0.56%) As of 11:51 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock IRMD vs. SLNO, NVST, LIVN, WRBY, INSP, LQDA, PRCT, LMAT, AORT, and EYEShould you be buying iRadimed stock or one of its competitors? The main competitors of iRadimed include Soleno Therapeutics (SLNO), Envista (NVST), LivaNova (LIVN), Warby Parker (WRBY), Inspire Medical Systems (INSP), Liquidia Technologies (LQDA), PROCEPT BioRobotics (PRCT), LeMaitre Vascular (LMAT), Artivion (AORT), and National Vision (EYE). These companies are all part of the "medical equipment" industry. iRadimed vs. Its Competitors Soleno Therapeutics Envista LivaNova Warby Parker Inspire Medical Systems Liquidia Technologies PROCEPT BioRobotics LeMaitre Vascular Artivion National Vision Soleno Therapeutics (NASDAQ:SLNO) and iRadimed (NASDAQ:IRMD) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their media sentiment, institutional ownership, valuation, profitability, analyst recommendations, risk, dividends and earnings. Do analysts prefer SLNO or IRMD? Soleno Therapeutics currently has a consensus price target of $115.09, indicating a potential upside of 71.85%. iRadimed has a consensus price target of $72.00, indicating a potential upside of 1.08%. Given Soleno Therapeutics' stronger consensus rating and higher probable upside, equities analysts plainly believe Soleno Therapeutics is more favorable than iRadimed.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Soleno Therapeutics 0 Sell rating(s) 0 Hold rating(s) 11 Buy rating(s) 1 Strong Buy rating(s) 3.08iRadimed 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Is SLNO or IRMD more profitable? iRadimed has a net margin of 26.61% compared to Soleno Therapeutics' net margin of 0.00%. iRadimed's return on equity of 23.30% beat Soleno Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Soleno TherapeuticsN/A -73.74% -56.67% iRadimed 26.61%23.30%20.62% Which has stronger valuation and earnings, SLNO or IRMD? iRadimed has higher revenue and earnings than Soleno Therapeutics. Soleno Therapeutics is trading at a lower price-to-earnings ratio than iRadimed, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSoleno Therapeutics$32.66M108.99-$175.85M-$4.14-16.18iRadimed$73.24M12.37$19.23M$1.6243.97 Which has more volatility and risk, SLNO or IRMD? Soleno Therapeutics has a beta of -2.72, suggesting that its stock price is 372% less volatile than the S&P 500. Comparatively, iRadimed has a beta of 1.02, suggesting that its stock price is 2% more volatile than the S&P 500. Does the media favor SLNO or IRMD? In the previous week, Soleno Therapeutics had 10 more articles in the media than iRadimed. MarketBeat recorded 16 mentions for Soleno Therapeutics and 6 mentions for iRadimed. Soleno Therapeutics' average media sentiment score of 1.10 beat iRadimed's score of 0.81 indicating that Soleno Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Soleno Therapeutics 10 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive iRadimed 3 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do institutionals and insiders have more ownership in SLNO or IRMD? 97.4% of Soleno Therapeutics shares are owned by institutional investors. Comparatively, 92.3% of iRadimed shares are owned by institutional investors. 6.4% of Soleno Therapeutics shares are owned by company insiders. Comparatively, 36.8% of iRadimed shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth. SummaryiRadimed beats Soleno Therapeutics on 9 of the 17 factors compared between the two stocks. Get iRadimed News Delivered to You Automatically Sign up to receive the latest news and ratings for IRMD and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding IRMD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart IRMD vs. The Competition Export to ExcelMetriciRadimedMED INSTRUMENTS IndustryMedical SectorNASDAQ ExchangeMarket Cap$906.11M$6.85B$5.76B$9.85BDividend Yield0.94%1.19%6.66%4.48%P/E Ratio43.9725.4182.2726.62Price / Sales12.3754.14534.88109.99Price / Cash45.7822.4425.7028.92Price / Book9.616.9410.816.59Net Income$19.23M$174.83M$3.28B$265.93M7 Day Performance-3.55%0.11%0.23%-0.26%1 Month Performance7.65%3.99%10.66%6.61%1 Year Performance55.45%8.49%51.27%22.69% iRadimed Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)IRMDiRadimed4.8327 of 5 stars$71.23-0.6%$72.00+1.1%+52.5%$906.11M$73.24M43.97110Positive NewsSLNOSoleno Therapeutics4.5621 of 5 stars$66.51-3.0%$115.09+73.0%+37.3%$3.64BN/A-16.0730Positive NewsNVSTEnvista3.7916 of 5 stars$21.15-2.6%$20.92-1.1%+13.3%$3.61B$2.51B66.1012,300News CoveragePositive NewsLIVNLivaNova1.7309 of 5 stars$56.35+0.8%$59.71+6.0%+13.0%$3.05B$1.25B-14.492,900News CoveragePositive NewsAnalyst ForecastWRBYWarby Parker1.7707 of 5 stars$26.18-3.1%$24.06-8.1%+71.6%$2.84B$771.32M-373.883,780Positive NewsINSPInspire Medical Systems4.9942 of 5 stars$93.20-2.9%$165.62+77.7%-47.4%$2.84B$802.80M53.881,246Positive NewsAnalyst ForecastInsider TradeLQDALiquidia Technologies3.3061 of 5 stars$26.25-2.2%$32.11+22.3%+200.5%$2.31B$14M-15.4450Trending NewsInsider TradeOptions VolumePRCTPROCEPT BioRobotics3.6713 of 5 stars$39.31-4.7%$74.88+90.5%-49.9%$2.29B$224.50M-25.36430Positive NewsAnalyst UpgradeLMATLeMaitre Vascular3.03 of 5 stars$97.60-2.7%$97.60+5.2%$2.27B$219.86M47.38490Positive NewsAORTArtivion3.3075 of 5 stars$43.53-2.9%$40.63-6.7%+60.9%$2.12B$388.54M-103.641,600EYENational Vision3.6044 of 5 stars$23.93-3.6%$24.73+3.3%+107.8%$1.97B$1.82B-132.9413,411Positive News Related Companies and Tools Related Companies SLNO Competitors NVST Competitors LIVN Competitors WRBY Competitors INSP Competitors LQDA Competitors PRCT Competitors LMAT Competitors AORT Competitors EYE Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:IRMD) was last updated on 9/3/2025 by MarketBeat.com Staff From Our PartnersHow “Trump’s New Dollar” Could Impact Your WealthPresident Trump just signed a game-changing law… That could soon upgrade the U.S. dollar in your checking a...Brownstone Research | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | SponsoredWhat's the Best Way to Lower RMD Taxes?Turning 73 triggers a key IRS rule: you must begin taking required minimum distributions (RMDs) from certain r...SmartAsset | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredWhat Steve Bannon revealed about Trump’s gold playA Trump advisor just said 3 words that could reset the dollar. It’s a gold move nobody saw coming—and your ...Reagan Gold Group | SponsoredWarren Buffett Issues Cryptic Warning on U.S. DollarImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe $365M annual revenue crypto play While Bitcoin generates zero operational revenue, one DeFi protocol qu...Crypto 101 Media | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding iRadimed Corporation Please log in to your account or sign up in order to add this asset to your watchlist. Share iRadimed With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
